Signature Genomic Laboratories, a company that specializes in microarray-based diagnostic testing of genetic disease in individuals with mental retardation and birth defects, announced it has waived the 25% deposit previously required of patients for insurance billing.
Rather than pay a deposit prior to the initiation of testing, patients with private insurance can request an insurance benefits investigation prior to or concurrent with sample processing through Signature’s recently introduced Patient Advocacy Program. Signature’s Patient Advocacy Team will communicate with the patient’s insurance carrier on the patient’s behalf to determine coverage.
“Many of our patients are already financially responsible for other testing and treatment,” said Catherine D. Kashork, Director of Operations at Signature. “By eliminating the 25% deposit, we remove another barrier to timely testing and reduce the burden on these families.”
Signature Genomic Laboratories’ Patient Advocacy Program is designed to assist patients and their families with obtaining insurance coverage for microarray analysis. Through the program, Signature’s Patient Advocacy Team will communicate with the patient’s insurance carrier on the patient’s behalf to determine the benefits available for clinical laboratory testing. If the insurance carrier refuses to pay for all or part of the charge, the Patient Advocacy Team will work with the patient to submit an appeal or develop an alternate payment plan.
Source: BusinessWire
